NYXH Nyxoah

Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023

Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023

Nyxoah to Release Second Quarter 2023 Financial Results

on August 8, 2023

Mont-Saint-Guibert, Belgium – July 27, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter of 2023 on Tuesday, August 8, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: . For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: . After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit .

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:

Nyxoah

David DeMartino, Chief Strategy Officer



Attachment



EN
27/07/2023

Underlying

NYXHNyxoah

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
03/23/26 March 23, 2026 1 FR
 PRESS RELEASE
Free
NYXH NYXOAH

Publication relating to transparency notifications

Publication relating to transparency notifications REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), March 20, 2026, 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Robert Taub / Robelga SRL On March 19, 2026, Nyxoah received a transparency notification from Robert Taub and related person Robelga SRL, following the crossing above the 3% thresho...

March 20, 2026 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Publication relative à des notifications de transparence

Publication relative à des notifications de transparence INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 20 mars 2026, 22:30h CET / 17:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu une notification de transparence comme détaillée ci-dessous. Robert Taub / Robelga SRL Le 19 mars 2026, Nyxoah a reçu une notification de transparence de Robert Taub et d’une personne liée, Robelga SRL, à la...

March 20, 2026 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Publication relating to transparency notification

Publication relating to transparency notification REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), March 13, 2026, 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BNP Paribas Asset Management On March 11, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management SA. Based on the notification, BNP Paribas Asset Managem...

March 13, 2026 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Publication relative à une notification de transparence

Publication relative à une notification de transparence INFORMATION RÉGLEMENTÉE Publication relative à une notification de transparence Mont-Saint-Guibert (Belgique), le 13 mars 2026, 22:30h CET / 17:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu une notification de transparence comme détaillée ci-dessous. BNP Paribas Asset Management Le 11 mars 2026, Nyxoah a reçu une notification de transparence de BNP Paribas Asset Management SA. Sur la base de la ...

March 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch